Studies on a circulating anticoagulant in procainamide-induced lupus erythematosus.
Circulating anticoagulant activity that had at least two distinct mechanisms--one directed against factor XII and one directed against blood thromboplastin (prothrombin activator complex)--developed in a patient with clinical and laboratory evidence of procainamide hydrochloride-induced systemic lupus erythematosus. The anticoagulant activity behaved as a gamma-globulin in chromatographic and electrophoretic analyses, with the majority of activity behaving as an IgM immunoglobulin. Despite markedly abnormal coagulation study results, no clinical bleeding occurred. Anticoagulant activity paralleled clinical and laboratory evidence of the inflammatory disease and improved on discontinuance of procainamide therapy.
D000368:Aged; D001777:Blood Coagulation; D001780:Blood Coagulation Tests; D006801:Humans; D007075:Immunoglobulin M; D007136:Immunoglobulins / Q000032:analysis* / Q000494:pharmacology; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000139:chemically induced*; D008297:Male; D011342:Procainamide / Q000009:adverse effects*; D005719:gamma-Globulins
D007075:Immunoglobulin M; D007136:Immunoglobulins; C019158:circulating anticoagulants; D005719:gamma-Globulins; D011342:Procainamide